# Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

> **NCT01928576** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 143 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Epigenetic Therapy

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Entinostat
- **DRUG:** Nivolumab
- **DRUG:** CC-486 300

## Key facts

- **NCT ID:** NCT01928576
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-06
- **Primary completion:** 2023-04-04
- **Final completion:** 2023-04-04
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2024-05-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928576, "Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01928576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*